ADCAN, MS Pharma Plan UAE Production of Cancer and Chronic-Disease Medicines

The agreement covers injectables, tablets and biosimilars. ADCAN also plans UAE laboratory capacity for monoclonal-antibody quality testing.
This is a short summary. The full story is published by Econotimes.
Read full story at Econotimes


